Neurimmune Welcomes Biogen's News on Clinical Benefit of Aducanumab
Zurich, Switzerland – October 22, 2019 – Neurimmune welcomes the news that Biogen plans regulatory filing for aducanumab in Alzheimer's disease based on a new analysis of a larger data set from Phase 3 studies. Neurimmune discovered aducanumab together with a team of researchers at the University of Zurich. In 2007 Neurimmune and Biogen entered into a collaborative development and license agreement for aducanumab's development and commercialization.
"Today's news marks a substantial advancement in neuroscience. This is long-awaited progress in finding a treatment for Alzheimer's disease," said Roger Nitsch, CEO and President of Neurimmune. "For decades, patients, families and caregivers have been hoping for a scientific breakthrough leading to clinical benefit."
For the first time, large late-stage clinical study results showed that removal of amyloid in the brain can translate into clinically meaningful effects on both cognition and function in patients with Alzheimer's disease. Aducanumab - the antibody mediating amyloid removal - was among the first human antibodies Neurimmune developed through its Reverse Translational Medicine platform. This technology translates antibody-encoding genetic information obtained from human white blood cells into therapeutic antibodies.
"This continues to be a fascinating journey, from a small team of passionate scientists experimenting in the university lab, to prototyping by a startup biotech company, to creating a world-wide multidisciplinary collaboration of thousands of dedicated researchers, antibody manufacturing experts, clinical investigators and study nurses," said Roger Nitsch. "Today, we are moving a meaningful step closer toward our joint goal of delivering a treatment for Alzheimer's disease."
Neurimmune's team of scientists and clinical experts is committed to delivering innovative therapies by focusing on science-driven discoveries and early clinical development of new drug candidates. The company's entrepreneurial business model permits a high degree of independent decision making. It relies on strategic collaborations with selected industry partners for late-stage clinical development and commercialization, with those collaborations providing independent financing to fund Neurimmune's business operations and research and development engine.
Aducanumab (BIIB037) is an investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease. Neurimmune licensed aducanumab to Biogen under a collaborative development and license agreement. Since 2017 Biogen and Eisai have collaborated on the development and commercialization of aducanumab globally.
EMERGE and ENGAGE were Phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate the efficacy and safety of aducanumab. The primary objective of the studies was to evaluate the efficacy of monthly doses of aducanumab as compared with placebo in reducing cognitive and functional impairment as measured by changes in the CDR-SB score. Secondary objectives were to assess the effect of monthly doses of aducanumab as compared to placebo on clinical decline as measured by MMSE, ADAS-Cog 13 and ADCS-ADL-MCI.
Neurimmune is a biopharmaceutical company translating B-cell derived genetic information of human immune repertoires into transformative antibody therapeutics. Neurimmune develops drug candidates for CNS and protein aggregation diseases including Alzheimer’s and Parkinson’s diseases, amyotrophic lateral sclerosis, frontotemporal dementia and dementia with Lewy bodies. Neurimmune’s most advanced drug candidate in clinical Phase 3 development is aducanumab for the treatment of Alzheimer's disease. Four additional drug candidates from Neurimmune are in clinical Phases 2 and 1; four further programs are in pre-clinical development, and over ten programs are in research discovery stages. Besides recombinant human monoclonal antibodies discovered through the Reverse Translational Medicine platform, Neurimmune has recently expanded the spectrum of its treatment modalities by a small chemical molecule and by programs around vectorized expression of human antibody genes.
Contact for Media:
Martin Meier-Pfister, +41 43 244 8140
Neurimmune Welcomes Biogen's News on Clinical Benefit of Aducanumab
Neurimmune and TVM Capital Life Science Announce the Initiation of AL-S Pharma’s Phase 1 Study of AP-101 for the Treatment of ALS
Neurimmune and REGENXBIO Announce Collaboration to Develop Vectorized Antibodies for the Treatment of Neurodegenerative Diseases
Biogen and Eisai to discontinue Phase 3 ENGAGE and EMERGE trials of Aducanumab
Neurimmune-led research consortium receives Target ALS discovery grant
NovaGo Therapeutics raises CHF 10 million to develop regenerative anti-Nogo therapy for stroke
Neurimmune appoints John Dellapa as General Counsel
Neurimmune announces publication in Science Translational Medicine
Neurimmune appoints Natascha Schill as VP Project & Alliance Management
Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Neurimmune Achieves Milestone in Collaboration with Ono Pharmaceutical
Neurimmune appoints Christoph Hock as Chief Medical Officer to lead clinical development
Biogen and Eisai report data from long-term extension Phase 1b study of investigational Alzheimer's disease treatment Aducanumab
Michael Salzmann honored as Corporate Professional of the Year by The M&A Advisor
Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab
Neurimmune announces additional collaboration with Biogen on human-derived antibodies for neurodegenerative diseases
Neurimmune appoints Fabian Buller as Chief Business Officer
In January 2018, Biogen dosed the first patient in the Phase 2 SPARK study of BIIB054 (anti-alpha-synuclein antibody) in Parkinson's disease.
Neurimmune Announces Collaboration with Ono Pharmaceutical in Neurodegenerative Diseases Field
Neurimmune Raises $150 Million to Finance its Growth Strategy
Biogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
BIIB076 Moves into Phase 1 for Alzheimer's Disease
Neurimmune's joint research project with University of Zurich awarded Pfizer Research Prize 2017.
Foreign Policy magazine recognized Neurimmune's president Roger Nitsch among the 100 Leading Global Thinkers 2016
Biogen Presents Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer’s Disease Meeting
Neurimmune and TVM Capital Life Science Announce Creation of AL-S Pharma to Develop Innovative Therapy for Patients with ALS
Aducanumab Granted FDA Fast Track Designation and Recent Interim Analysis from PRIME Consistent with Results Previously Reported
Early Results Show Aducanumab Removes Amyloid Plaques in Patients with Alzheimer's Disease
Aducanumab accepted into EMA's PRIME Program
BIIB076 (anti-tau mAb) moving into pre-IND toxicology studies
Neurimmune’s data on its broadly neutralizing human monoclonal JC polyomavirus VP1–specific antibodies as candidate therapeutics for PML published in Science Translational Medicine
Roger Nitsch honored at Alzheimer's translation and therapeutic panel and luncheon by the American Federation for Aging Research (AFAR)
Neurimmune Receives Major Development Milestone upon Initation of Global Phase 3 Studies with Aducanumab for Early Alzheimer’s Disease
Ramot at Tel Aviv University Ltd. and Neurimmune Announce Sponsored Research Agreement for Alzheimer's Disease Treatment
Biogen Presents New Data from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at Alzheimer’s Association International Conference® 2015
BIIB054 reached significant milestone
Biogen Idec Presents Positive Interim Results from Phase 1b Study at 2015 AD/PD Conference
Aducanumab (BIIB037) showed significant time and dose dependent reduction of beta amyloid in the brain of AD patients
Christoph Hock nominated as VP at the University of Zurich
Aducanumab (BIIB037) for the treatment of Alzheimer’s disease reduced brain beta-amyloid levels in a Phase 1b trial
ALS Therapy Development Institute and Neurimmune Partner to Advance Treatments for ALS
Human-Derived SOD1 Antibodies Show Promise in ALS Mice
Biogen presents the first clinical data from an ongoing Phase 1 study of BIIB037 in mild to moderate Alzheimer’s
Biogen Idec began a double-blind, placebo-controlled Phase Ib trial
Neurimmune acquires USD 1.9m funding from Swiss CTI
Biogen Idec submitted an investigational new drug (IND) application
Neurimmune introduced BIIB037
Biogen Idec and Neurimmune announce agreement on three neurodegenerative disease programs
Neurimmune awarded the 2010 ZKB TECHNOPARK® Pioneer Award
Neurimmune Therapeutics Announces Advancement of Alzheimer's Program into Preclinical Development
New facility at the Bio-Technopark Zurich in Schlieren
Biogen Idec and Neurimmune Therapeutics announce alliance to develop treatments for Alzheimer’s disease